- Topic
41k Popularity
50k Popularity
15k Popularity
3k Popularity
2k Popularity
- Pin
- 🎉 Attention Alpha fans! Alpha’s latest TAG airdrop goes live today at 10 AM—first come, first served!
💰 Don’t forget to share your airdrop or points screenshot on Gate Square with the hashtag #ShowMyAlphaPoints# for a chance to win a share of the $200 token mystery box!
🥇 Top points winner: $100
✨ 5 outstanding posts: $20 each
📸 Pro tips:
Add a caption like “I earned ____ with Alpha. So worth it”
Share your points-earning tips or redemption experience for a better chance to win!
📅 Activity deadline: August 10, 18:00 UTC
Let’s go! See you tonight: https://www.gate.com/announcements/article - Hey fam—did you join yesterday’s [Show Your Alpha Points] event? Still not sure how to post your screenshot? No worries, here’s a super easy guide to help you win your share of the $200 mystery box prize!
📸 posting guide:
1️⃣ Open app and tap your [Avatar] on the homepage
2️⃣ Go to [Alpha Points] in the sidebar
3️⃣ You’ll see your latest points and airdrop status on this page!
👇 Step-by-step images attached—save it for later so you can post anytime!
🎁 Post your screenshot now with #ShowMyAlphaPoints# for a chance to win a share of $200 in prizes!
⚡ Airdrop reminder: Gate Alpha ES airdrop is - Gate Futures Trading Incentive Program is Live! Zero Barries to Share 50,000 ERA
Start trading and earn rewards — the more you trade, the more you earn!
New users enjoy a 20% bonus!
Join now:https://www.gate.com/campaigns/1692?pid=X&ch=NGhnNGTf
Event details: https://www.gate.com/announcements/article/46429 - Hey Square fam! How many Alpha points have you racked up lately?
Did you get your airdrop? We’ve also got extra perks for you on Gate Square!
🎁 Show off your Alpha points gains, and you’ll get a shot at a $200U Mystery Box reward!
🥇 1 user with the highest points screenshot → $100U Mystery Box
✨ Top 5 sharers with quality posts → $20U Mystery Box each
📍【How to Join】
1️⃣ Make a post with the hashtag #ShowMyAlphaPoints#
2️⃣ Share a screenshot of your Alpha points, plus a one-liner: “I earned ____ with Gate Alpha. So worth it!”
👉 Bonus: Share your tips for earning points, redemption experienc - 🎉 The #CandyDrop Futures Challenge is live — join now to share a 6 BTC prize pool!
📢 Post your futures trading experience on Gate Square with the event hashtag — $25 × 20 rewards are waiting!
🎁 $500 in futures trial vouchers up for grabs — 20 standout posts will win!
📅 Event Period: August 1, 2025, 15:00 – August 15, 2025, 19:00 (UTC+8)
👉 Event Link: https://www.gate.com/candy-drop/detail/BTC-98
Dare to trade. Dare to win.
Hims & Hers stock slides 5% after second quarter revenue misses forecasts
Hims & Hers Health (HIMS) stock fell as much as 5% early Tuesday after the company reported revenue late Monday that fell shy of Wall Street forecasts while maintaining its full-year forecast.
The telehealth company posted revenue of $544.8 million in the second quarter, marking a 73% increase year over year but missing analyst estimates for $552 million, according to Bloomberg data. Hims & Hers maintained its full-year revenue guidance of $2.3 billion to $2.4 billion.
Earnings per share topped forecasts, coming in at $0.17 against expectations for $0.15.
The stock had dropped as much as 11% in premarket trade.
NYSE - Nasdaq Real Time Price • USD # (HIMS)
The company's slide comes after drugmaker Novo Nordisk (NVO) ended a short-lived partnership between the two companies in June that saw Novo Nordisk allow Hims & Hers access to its viral weight-loss drug Wegovy.
Novo Nordisk alleged in the announcement that Hims & Hers "has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk."
Novo Nordisk stock fell more than 21% last month after the drugmaker announced it was slashing profit forecasts for Wegovy and its diabetes treatment Ozempic.
In August 2022, the US Federal Drug Administration (FDA) allowed compounding pharmacies, including those working with telehealth providers like Hims & Hers, to copy and distribute semaglutide weight-loss and weight-management drugs due to shortages in brand-name products like Wegovy and Eli Lilly's (LLY) Zepbound after massive consumer demand.
The move allowed Hims & Hers to market a GLP-1 weight-loss drug itself while the shortage was in place, which it began doing in May 2024, according to the Financial Times. But the FDA ended that order in February, citing that the shortage of brand-name GLP-1s had ended and ordering compounding pharmacies to stop production by April.
Coming off the FDA ruling, Hims & Hers is trying to diversify its product offerings. Management announced in May in a Q1 shareholder letter that its "vision involves expanding from hundreds of personalized treatments today to potentially thousands."
Still, the company's stock has been a big winner this year relative to GLP-1 leaders like Novo Nordisk and Eli Lilly, rising more than 150% year to date against a more than 40% slide for Novo Nordisk shares. Eli Lilly stock is roughly flat this year.
"The momentum we saw through the first half of 2025 is proof that our platform is delivering exactly what millions of people have been waiting for, access to personalized, high-quality care that meets people where they are," CEO Andrew Dudum said during the Hims & Hers Q2 earnings call.
Story Continues"From the beginning, we have believed that medicine should be centered on the individual, not the system. We are now seeing the market demanding just that. What we have built is working and it's working at scale."
Jake Conley is a breaking news reporter covering US equities for Yahoo Finance. Follow him on X at @byjakeconley or email him at jake.co**nley@yahooinc.com.
View Comments